• Search MS Observer

   

• Categories

  • News
  • Personal Stories
  • Research
  • Work & Disability

• Recent Comments

  • Janel Mitchell on Two Woman Climbers with Multiple Sclerosis Near Summit of Mt Everest in Lead Up to First World MS Day
  • Gary Mullennix on MS expert downplays Italian surgeon’s treatment
  • Tee on Stem Cell Tourists Denied: Costa Rica Stops Treatments at Top Clinic
  • Multiple Sclerosis on O’Jays Singer Reveals Long Battle With Multiple Sclerosis
  • wyfinti on Chemical in Marijuana to Slow Multiple Sclerosis?

• Recent Posts

  • Hopes for reversing age-associated effects in MS patients
  • Canadian dies following MS surgery in U.S.
  • Multiple sclerosis changes Garland man’s outlook on marijuana
  • Multiple Sclerosis Changes With the Seasons
  • MS Patient, Singer Gives to Others – WSJ.com
  • Multiple sclerosis theory dealt a blow by studies – Los Angeles Times
  • Doc calls costly therapy ‘robbery’
  • Stem Cell Tourists Denied: Costa Rica Stops Treatments at Top Clinic
  • Vitamin D Linked to Poor Learning Performance in Patients With MS
  • O’Jays Singer Reveals Long Battle With Multiple Sclerosis
  • Liberation or placebo effect?
  • Twin Study Deepens Multiple Sclerosis Mystery
  • UV Radiation, Not Vitamin D, Might Limit Multiple Sclerosis Symptoms
  • Discovery May Lead to Better Multiple Sclerosis Treatments – BusinessWeek
  • Learning to Trust Myself

• Archives

  • January 2012
  • July 2011
  • October 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008

•  

   

   

   

ScienceDaily (May 2, 2008) — The antidepressant Prozac may help to curb disease activity in the relapsing remitting form of multiple sclerosis (MS), reveals preliminary research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.The research team randomly allocated 40 patients with the relapsing remitting form of MS to treatment with either 20 mg daily of fluoxetine (Prozac) or an inactive substance (placebo) for a period of 24 weeks.

Detailed brain scans (magnetic resonance images or MRI) every four weeks were used to check for new areas of neurological inflammation, a hallmark of active disease. In total, 38 patients–19 in each group–completed the study. The scans showed that those in the placebo group had more new areas of inflammation than those treated with Prozac.

The effects began to become evident after eight weeks, which corresponds to the time the selective serotonin reuptake inhibitor (SSRI) class of drugs, of which Prozac is one, start to work on relieving depression.

read more: Prozac May Help Curb Disease Activity In Multiple Sclerosis

Comments

• Blogroll

  • Mayo Clinic – Multiple Sclerosis
  • National Multiple Sclerosis Society
  • This is MS
  • Wikipedia on MS

• Communities

  • Living with Multiple Sclerosis
  • MS World Forums
  • Patients Like Me

• Resources

  • Living with Multiple Sclerosis
  • MS World
  • Patients Like Me
  • Understanding Multiple Sclerosis

•  

   

   

   

•  

   

   

• Important Notice

  This site posts excerpts and summaries of articles of interest to people with multiple sclerosis and their families, along with links to the full articles in the journals in which they were published.

  I have multiple sclerosis (primary progressive), but I am neither a doctor nor a research scientist. I have no connection to the people mentioned in these articles, and have no more information about the subject of any given article than is contained in the article itself. Please do not ask me for medical advice or how to contact people mentioned in these articles. If contact information is not contained in the article itself, your best bet is to Google the name of the person, company or clinic you are seeking.